Defence Therapeutics launch Accum-mRNA vaccine programme
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement...
Defence’s novel Accutox intranasal reduces 50% of cancer nodules
Defence Therapeutics, a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, has just completed a pre-clinical study using...
Defence Therapeutics are using Accum technology in mRNA vaccines
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its...
How dangerous is mould in the home?
Amid the rise of mould-related health incidents in the UK, Gama Healthcare investigates what can be done to combat the risk of mould in...
Adopt point-of-care diagnostics to cut carbon emissions, say over 80% of GPs
A new study by LumiraDX has found that the majority of the GP workforce believes that point-of-care diagnostics could cut carbon emissions.
Point-of-care diagnostics must...
Defence Therapeutics to begin phase 1 trial for new anti-cancer treatment
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful...
Defence’s successful study on the ACCUVAC-PT007 vaccine
Defence Therapeutics Inc. has announced its successful study on its ACCUVAC-PT007 vaccine, which targets cervical cancer.
Defence Therapeutics Inc. a Canadian biopharmaceutical company specialised in...
LumiraDx continue rapid microfluidic immunoassay HbA1c test expansion
LumiraDx's rapid microfluidic immunoassay HbA1c test will now be available in Europe, parts of the Middle East, Asia, Latin America, and Africa.
Early customers...
Luxembourg government approve Azenta MoU on cold chain solutions
Azenta, Inc. and the Government of Luxembourg today announced the signing of a Memorandum of Understanding (MoU) to facilitate continued healthcare technology and the...
Defence Therapeutics applies Accum technology to anti-cancer vaccine
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is initiating a new research and...
Defence Therapeutics launches new AccuTOX lung cancer treatment
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start...
Secop Group and B Medical Systems announce cold chain solution partnership
A new agreement between Secop Group and B Medical Systems will provide new cold chain solutions for the transportation of vaccines, biospecimens and temperature-sensitive...
Defence Therapeutics have been granted patents for their antibody-drug conjugate technology
Defence Therapeutics is pleased to announce that notices of allowance have been issued by the Japanese and Israeli Patent Offices for patent application no....
Diagnostic technology is central to tackling pandemics
“Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” according to LumiraDx and the...
Accum A1-reprogrammed vaccine cured 80% of animals with pre-established lymphoma
Defence Therapeutics Inc, a Canadian biopharmaceutical company specialising in developing immune-oncology vaccines and drug delivery technologies, are pleased to report that Defence’s novel vaccine...
Defence Therapeutics applauds US President’s anti-cancer initiative
Defence Therapeutics Inc, a Canadian biotech company actively working on accelerating scientific discoveries an products development against cancer, congratulates US President, Joe Biden on...
LumiraDx’s COVID-19 antigen test is the only test exceeding WHO’s desirable sensitivity target
In a Cochrane meta-analysis of 152 studies investigating over 100,000 nose and throat samples and 20 brands of COVID-19 tests, only the LumiraDx assay...
Defence’s ACCUMTM variant “A1” converts mesenchymal stromal cells into potent antigen presenting cells
Defence Therapeutics has announced groundbreaking news about the development of a novel anti-cancer cellular vaccine using reprogrammed mesenchymal stromal cells.
Defence Therapeutics Inc., a Canadian...
Azenta announces acquisition of B Medical Systems
Azenta Inc. has announced its agreement to acquire B Medical Systems, a market leader in temperature-controlled storage and transportation solutions.
In an exciting development, Azenta...
Defence Therapeutics receives US patent for its ADC Platform Technology
In an exciting development, Defence Therapeutics has received a US patent covering its ADC Platform Technology.
In the latest announcement on August 8th, 2022, Defence...